Minireviews
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. May 15, 2025; 16(5): 100590
Published online May 15, 2025. doi: 10.4239/wjd.v16.i5.100590
Immunosuppressive agents in diabetes treatment: Hope or despair?
Lu Li, Xi Yang, Jin-Shuai Ren, Ming-Zhu Huang, Qing-Wei Zhao
Lu Li, Xi Yang, Jin-Shuai Ren, Ming-Zhu Huang, Qing-Wei Zhao, Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China
Co-corresponding authors: Ming-Zhu Huang and Qing-Wei Zhao.
Author contributions: Li L, Huang MZ and Zhao QW contributed to design the work; Li L, Yang X and Ren JS contributed to perform the research and analyzed the data; Li L, Huang MZ and Zhao QW contributed to drafted and revised the work; All authors have read and approved the final manuscript. Huang MZ and Zhao QW contributed equally to this paper as co-corresponding authors. Both Huang MZ and Zhao QW have played important and indispensable roles in the article design and manuscript preparation as the co-corresponding authors. Huang MZ obtained the funds for this research project and was primarily responsible for the organization and review of the content related to type 2 diabetes and transplantation. Zhao QW designed, and supervised the whole process of the project, and was mainly in charge of the organization and review of the content related to type 1 diabetes.
Supported by The National Natural Science Foundation of China, No. 82273986; and Natural Science Foundation of Zhejiang Province, No. LYY22H310014.
Conflict-of-interest statement: The authors declare no conflict of interest.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ming-Zhu Huang, PhD, Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou 310003, Zhejiang Province, China. hmzj2002@zju.edu.cn
Received: August 21, 2024
Revised: January 19, 2025
Accepted: March 5, 2025
Published online: May 15, 2025
Processing time: 247 Days and 17.9 Hours
Core Tip

Core Tip: The exploration of immunosuppressive agents for diabetes treatment is gaining attention. Diabetes' complex etiology offers multiple therapeutic targets. These agents regulate the immune system, which plays a crucial role in diabetes pathogenesis. The review examines their potential in type 1 diabetes, type 2 diabetes, and transplantation. The review aims to reveal the potential and limitations of these therapies by summarizing current research on immunosuppressive agents in diabetes treatment and prevention.